Leeco Diagnostics, Inc.: FDA filings under this applicant name
FDA lists 49 510(k) clearances under the applicant name “Leeco Diagnostics, Inc.” (first 1979, latest 1989), across 23 product codes in 4 review panels. Median 510(k) review time under this name: 36 days. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 0 | — |
| 2013 | 0 | — |
| 2014 | 0 | — |
| 2015 | 0 | — |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 0 | — |
| 2019 | 0 | — |
| 2020 | 0 | — |
| 2021 | 0 | — |
| 2022 | 0 | — |
| 2023 | 0 | — |
| 2024 | 0 | — |
| 2025 | 0 | — |
| 2026 | 0 | — |
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| JHI | Visual, Pregnancy Hcg, Prescription Use | 10 | 10 |
| CDZ | Radioimmunoassay, Testosterones And Dihydrotestosterone | 4 | 4 |
| CEP | Radioimmunoassay, Luteinizing Hormone | 4 | 4 |
| CFT | Radioimmunoassay, Prolactin (Lactogen) | 3 | 3 |
| GTZ | Antisera, All Groups, Streptococcus Spp. | 3 | 3 |
| CDP | Radioimmunoassay, Total Triiodothyronine | 2 | 2 |
| CGJ | Radioimmunoassay, Follicle-Stimulating Hormone | 2 | 2 |
| DHA | System, Test, Human Chorionic Gonadotropin | 2 | 2 |
| JFH | Acid Phosphatase (Prostatic), Tartrate Inhibited | 2 | 2 |
| JLW | Radioimmunoassay, Thyroid-Stimulating Hormone | 2 | 2 |
Plus 13 more product codes.
Review panels
- Clinical Chemistry (40)
- Microbiology (4)
- Hematology (2)
- Immunology (2)
Most recent Leeco Diagnostics, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K895765 | LEECO PREVIEW(R) EBV (EIA) | KTN | 1989-10-31 | 35 |
| K894122 | LEECO VIS-DISK STREP-A (EIA) | GTZ | 1989-08-15 | 64 |
| K891096 | VIS-DISK HCG (EIA) JPL-041M | DHA | 1989-06-16 | 106 |
| K891095 | VIS-DISK HCG (EIA) LYOPHILIZED JPL-044M | DHA | 1989-06-16 | 106 |
| K883269 | PRL-QUANT | CFT | 1988-09-13 | 41 |
| K880577 | CONCEP-7-BHCG | JHI | 1988-03-15 | 34 |
| K880069 | LEECO PREGNASTICK (EIA) CATALOG #003 | LCX | 1988-02-11 | 31 |
| K870259 | VIS-CUBE HCG (EIA) LYOPHILIZED JPL-044 | JHI | 1987-03-10 | 46 |
| K864170 | LEECO VIS-CUBE STREP A (EIA) | GTZ | 1987-02-03 | 102 |
| K863999 | VIS-CUBE PREGNANCY HOME TEST,CAT. # JPL-042 | LCX | 1987-01-09 | 87 |
39 earlier clearances. See the full list in Caduvo.
Recalls
FDA recall records list no recalls under a recalling firm named Leeco Diagnostics, Inc..
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Frequently asked questions
How many FDA 510(k) clearances are listed under Leeco Diagnostics, Inc.?
FDA lists 49 510(k) clearances under the applicant name “Leeco Diagnostics, Inc.” (first 1979, latest 1989), across 23 product codes in 4 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Leeco Diagnostics, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Leeco Diagnostics, Inc. is 36 days.
Which FDA product codes appear under Leeco Diagnostics, Inc.?
The most frequent FDA product codes under this applicant name are JHI (Visual, Pregnancy Hcg, Prescription Use, 10); CDZ (Radioimmunoassay, Testosterones And Dihydrotestosterone, 4); CEP (Radioimmunoassay, Luteinizing Hormone, 4).
Next steps
- See all 49 Leeco Diagnostics, Inc. clearances with predicates and recalls
- Run predicate analysis for product code JHI, Leeco Diagnostics, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant name shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.